Results 251 to 260 of about 106,022 (294)
Some of the next articles are maybe not open access.
Spending on Glucagon-Like Peptide-1 Receptor Agonists Among US Adults
JAMA Network OpenThis economic evaluation estimates annual total US spending on glucagon-like peptide-1 receptor agonists from 2018 to 2023.
Stavros Tsipas +4 more
semanticscholar +1 more source
Renal protection with glucagon-like peptide-1 receptor agonists
Current Opinion in Pharmacology, 2020There is an unmet need for renoprotective drugs for more pronounced reduction of albuminuria beyond that provided by renin-angiotensin system (RAS) blockers and for effective slowdown of eGFR decline independent of albuminuria. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven effective in reducing prespecified secondary composite ...
Vitale M. +3 more
openaire +2 more sources
British Journal of Anaesthesia
Prescriptions and use of glucagon-like peptide-1 (GLP-1) receptor agonists are increasing dramatically, as indications are expanding from the treatment of diabetes mellitus to weight loss for people with obesity.
M. L. van Zuylen +5 more
semanticscholar +1 more source
Prescriptions and use of glucagon-like peptide-1 (GLP-1) receptor agonists are increasing dramatically, as indications are expanding from the treatment of diabetes mellitus to weight loss for people with obesity.
M. L. van Zuylen +5 more
semanticscholar +1 more source
[Glucagon-like peptide-1 receptor agonists].
Nihon rinsho. Japanese journal of clinical medicine, 2015Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire +1 more source
Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis
Current Opinion in RheumatologyPurpose of review This article synthesizes current preclinical and clinical literature regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in rheumatoid arthritis (RA), highlights mechanistic hypotheses and explores potential clinical roles and limitations of their use.
Ryan, Massay +2 more
openaire +2 more sources
The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
Current Medicinal ChemistryAbstract: Diabetes mellitus has become a serious life-threatening disease. As one of the new drugs for the treatment of diabetes, GLP-1 receptor agonists have attracted a lot of attention. Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists have good safety and tolerability. To a certain extent, they overcome the problem of the short
Haowen, Fang, Bing, Niu, Qin, Chen
openaire +2 more sources
Glucagon-Like Peptide-1 Receptor Agonists in Gynecologic Surgery
Obstetrics & GynecologyGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly expanded beyond their initial role in diabetes management to become prominent agents for weight loss and metabolic optimization. A growing number of patients receiving these therapies are presenting for gynecologic surgery. This narrative review summarizes current evidence on GLP-1 RAs,
Richard, Hsu +3 more
openaire +2 more sources
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Nature Reviews Cardiology, 2023J. Ussher, D. Drucker
semanticscholar +1 more source
Risks of Peri- and Post-Operative Complications With Glucagon-like Peptide-1 Receptor Agonists
Diabetes, obesity and metabolismTo assess whether adults with diabetes on oral hypoglycaemic agents undergoing general endotracheal anaesthesia during nine common surgical procedures who are glucagon‐like peptide‐1 receptor agonist (GLP1‐RA) users, compared with non‐users, are at ...
D. Klonoff +8 more
semanticscholar +1 more source